Premium
Novel treatment of refractory / recurrent pulmonary hepatoblastoma
Author(s) -
Zhang YuTong,
Chang Jian,
Yao Yunming,
Li Yanan,
Zhong Xiaodan,
Liu Ziling
Publication year - 2020
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.14134
Subject(s) - medicine , hepatoblastoma , refractory (planetary science) , topotecan , survival rate , surgery , medical record , chemotherapy , physics , astrobiology
Background There is no consensus about how to manage pulmonary metastasis in patients with hepatoblastoma. We reviewed a treatment with a combination of oxaliplatin, vincristine, and topotecan (OVT) paired with radiofrequency ablation (RFA) of 12 patients with multiple refractory / recurrent pulmonary hepatoblastoma. Methods The medical records from patients with ≤21 years of age presenting with multiple deposits (≥2) of refractory / recurrent pulmonary hepatoblastoma were reviewed. The following data were extracted from each patient: age, gender, histological subtyping, cycles of OVT, tumor size, biomarkers, chemotherapy regimen and dosage, RFA details, treatment response, follow up, and patient outcomes. The primary outcome measure was the complete response (CR) of pulmonary diseases, and secondary outcomes were event‐free survival rate and overall survival rate. Results Of 12 assessable patients, three (25%) (95% CI, 46.3–104) patients achieved PR (partial resopnse) after they finished OVT. After RFA, five (41.7%) (95% CI, 8.95–74.4) patients achieved CR (complete response). The 2 year event‐free survival rate was 33% (95% CI, 20.5–64.6). The 2 year overall survival for the study group was 41.7% (95% CI, 8.9–74.4). All toxicity events were handled satisfactorily and no toxic related deaths were observed. Conclusions Our review report shows that OVT combined with RFA can be a successful treatment modality for previously heavily treated refractory / recurrent pulmonary metastatic lesions from hepatoblastoma.